Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer: combo therapy enters phase 2 trial

NCT ID NCT07578337

Not yet recruiting Disease control Sponsor: Nelum Corp Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemotherapy alone. About 40 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCER UNTREATED

Contacts and locations

Locations

  • Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, La Coruña, Spain

    Contact

    Contact

  • Hospital Clínic Barcelona

    Barcelona, Barcelona, Spain

    Contact

    Contact

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

    Contact

    Contact

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, Spain

    Contact

    Contact

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga, Spain

    Contact

    Contact

  • Hospital Universitario de Donostia

    San Sebastián, Gipuzkoa, Spain

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.